3 ms·

Bad research by the reporter, from another Washington Post article: "That figured landed her the No. 1 spot on the Capital Business ranking of best compensated

by nieve 12y ago

Bad research by the reporter, from another Washington Post article: "That figured landed her the No. 1 spot on the Capital Business ranking of best compensated executives in the Washington region, and the No. 10 slot on a New York Times list of the highest compensated executives in the nation. " http://www.washingtonpost.com/business/capitalbusiness/united-therapeutics-slashes-pay-for-ceo-martine-rothblatt-after-shareholder-vote/2014/12/17/383992a8-861e-11e4-a702-fa31ff4ae98e_story.html http://www.washingtonpost.com/business/capitalbusiness/unite... It was also a huge jump from her normal compensation due to the company doing very well under her in 2013, so the shareholders turned around and immediately penalized her for good stock performance. I can understand adjusting a bit, but if your stock has shot up that much your investments have too and slashing your CEO's options by 2/3rds sounds greedy as hell. She agreed to amend her contract, but I doubt they could have forced her to short of removing her which would almost certainly hammer the stock price and triggered a golden parachute. Really bizarre move, all and all, and I've never heard of it happening to an executive of her caliber who's company is doing incredibly well.

nieve 12y ago
Ah, it may have been related to this (though I believe it came after): "The decision comes as officials also announced Rothblatt will share the CEO mantle beginning Jan. 1 with Roger Jeffs, who joined United Therapeutics in 1998 and currently serves as president and chief operating officer. He will become co-chief executive. Fisher said Jeffs’ promotion “reflects a division in responsibilities that the two of them have had for sometime.” Rothblatt focuses on long-term strategy and research, while Jeffs handles commercial operations and near-term research, he said. David Zaccardelli will subsequently be promoted to executive vice president and chief operating officer. Zaccardelli, who joined the company a decade ago, holds the titles of chief manufacturing officer and executive vice president of pharmaceutical development." So basically she'll be splitting her responsibilities with two guys and the CEO title with one of them and is giving up basically all operational control to focus on strategy and "long term research". Maybe that's a good choice and something she wants, but it looks a bit like a demotion. She may not have one foot out the door, but I'm guessing she's got ideas for a few more multi-billion dollar companies if she gets tired of UT.

by nieve 12y ago

nieve 12y ago

Ah, it may have been related to this (though I believe it came after): "The decision comes as officials also announced Rothblatt will share the CEO mantle beginning Jan. 1 with Roger Jeffs, who joined United Therapeutics in 1998 and currently serves as president and chief operating officer. He will become co-chief executive. Fisher said Jeffs’ promotion “reflects a division in responsibilities that the two of them have had for sometime.” Rothblatt focuses on long-term strategy and research, while Jeffs handles commercial operations and near-term research, he said. David Zaccardelli will subsequently be promoted to executive vice president and chief operating officer. Zaccardelli, who joined the company a decade ago, holds the titles of chief manufacturing officer and executive vice president of pharmaceutical development." So basically she'll be splitting her responsibilities with two guys and the CEO title with one of them and is giving up basically all operational control to focus on strategy and "long term research". Maybe that's a good choice and something she wants, but it looks a bit like a demotion. She may not have one foot out the door, but I'm guessing she's got ideas for a few more multi-billion dollar companies if she gets tired of UT.